National Research (NASDAQ:NRC) Releases Quarterly Earnings Results

National Research (NASDAQ:NRC) released its earnings results on Tuesday. The company reported $0.16 earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $35.19 million for the quarter. National Research had a net margin of 8.44% and a return on equity of 94.57%.

Here are the key takeaways from National Research’s conference call:

• TRCV reached $144.1 million (up 8% YoY) and marked five consecutive quarters of sequential TRCV growth, with 99% of revenue recurring, and management expects revenue growth to follow as TRCV converts in 2026.
• Q4 revenue was $35.2 million (down 5% YoY) and full-year revenue fell 4% to $137.4 million, driven by unusually heavy TRCV attrition in H2 2024 that created difficult year-over-year comparisons.
• Profitability remained strong with full-year adjusted EBITDA of $40.2 million (~29% margin) and Q4 adjusted EBITDA of $8.7 million, supporting continued investment while maintaining disciplined cost management.
• Go-to-market and product investments are gaining traction—full-year new sales rose 86% YoY, gross dollar retention hit a >7‑year high, and enablement products like Rounding (TRCV nearly doubled) plus AI enhancements are cited as key growth catalysts and cross-sell opportunities.
• Management reiterated a shareholder-friendly capital allocation approach, paying a quarterly dividend of 12 cents, maintaining opportunistic share repurchases, and preserving flexibility for strategic, accretive M&A.

National Research Stock Down 12.8%

Shares of NASDAQ:NRC opened at $15.37 on Thursday. The firm has a market cap of $348.28 million, a P/E ratio of 30.37 and a beta of 0.49. National Research has a 52-week low of $9.76 and a 52-week high of $22.79. The business’s 50 day simple moving average is $18.95 and its two-hundred day simple moving average is $15.90. The company has a debt-to-equity ratio of 5.31, a quick ratio of 0.53 and a current ratio of 0.53.

National Research Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, April 10th. Shareholders of record on Friday, March 27th will be issued a $0.16 dividend. The ex-dividend date is Friday, March 27th. This represents a $0.64 annualized dividend and a yield of 4.2%. National Research’s dividend payout ratio is presently 91.43%.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut National Research from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, January 28th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Institutional Trading of National Research

Several hedge funds have recently bought and sold shares of the business. Copeland Capital Management LLC bought a new position in shares of National Research in the fourth quarter valued at $65,000. Willis Investment Counsel boosted its stake in National Research by 1.6% during the 4th quarter. Willis Investment Counsel now owns 183,226 shares of the company’s stock valued at $3,439,000 after purchasing an additional 2,920 shares during the last quarter. Alliancebernstein L.P. increased its holdings in National Research by 6.3% during the 3rd quarter. Alliancebernstein L.P. now owns 18,499 shares of the company’s stock worth $236,000 after purchasing an additional 1,100 shares in the last quarter. Hotchkis & Wiley Capital Management LLC raised its stake in shares of National Research by 7.9% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 292,400 shares of the company’s stock worth $3,737,000 after purchasing an additional 21,450 shares during the last quarter. Finally, Two Sigma Investments LP lifted its holdings in shares of National Research by 99.0% in the third quarter. Two Sigma Investments LP now owns 60,912 shares of the company’s stock valued at $778,000 after purchasing an additional 30,296 shares in the last quarter. Institutional investors and hedge funds own 47.26% of the company’s stock.

National Research Company Profile

National Research Corp (NASDAQ: NRC), also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company’s cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.